<DOC>
	<DOCNO>NCT00892177</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also block growth tumor block blood flow tumor . It yet know whether bevacizumab together dasatinib effective placebo treat patient recurrent progressive high-grade glioma glioblastoma multiforme . PURPOSE : This randomized phase I/II trial ( Phase I complete ) study side effect best dose dasatinib give together bevacizumab see well work compare placebo treat patient recurrent progressive high-grade glioma glioblastoma multiforme .</brief_summary>
	<brief_title>Dasatinib Bevacizumab Treating Patients With Recurrent Progressive High-Grade Glioma Glioblastoma Multiforme</brief_title>
	<detailed_description>OUTLINE : This multicenter , phase I , dose-escalation study ( Phase I complete ) dasatinib follow phase II randomize study . Patients group accord study ( 1 vs 2 ) . Patients phase II portion stratify accord age ( &gt; 70 year age vs ≤ 70 year age ) , ECOG performance status ( 0 vs 1 2 ) . Phase I : Patients receive bevacizumab IV 30-90 minute day 1 . Patients also receive oral dasatinib twice daily day 1-14 maximum-tolerated dose ( MTD ) determine . Courses repeat every 14 day absence disease progression unacceptable toxicity . ( Phase I complete ) Please see Arms section Phase II treatment regimen . OBJECTIVES : PRIMARY OBJECTIVES : 1 . Determine maximum tolerate dose ( MTD ) dasatinib combination bevacizumab high grade glioma patient . ( Phase I ) 2 . To assess safety adverse event dasatinib combination bevacizumab patient population . ( Phase I ) 3 . To estimate efficacy bevacizumab combination dasatinib recurrent glioblastoma multiforme measure progression free survival six month compare efficacy bevacizumab alone . ( Phase II ) SECONDARY OBJECTIVES : 1 . To describe overall toxicity associate dasatinib/bevacizumab combination . ( Phase I ) 2 . To describe preliminary evidence antitumor activity . ( Phase I ) 3 . To assess time disease progression . ( Phase II ) 4 . To assess safety toxicity bevacizumab combination dasatinib patient population . ( Phase II ) 5 . To estimate efficacy bevacizumab combination dasatinib recurrent glioblastoma multiforme measure overall survival time compare efficacy bevacizumab alone . ( Phase II ) 6 . To assess impact treatment patient 's quality life ( QOL ) use overall score FACT-Br ( Phase II )</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patient Eligibility : I. Preregistration : 1 . Central pathology review submission . This review mandatory prior registration confirm eligibility . II . Registration 1 . ≥18 year age 2 . Study 1 : Histologic confirmation grade 3 4 glioma , include astrocytoma , oligodendroglioma , mixed glioma , determine preregistration central pathology review . 3 . Study 2 : Histological confirmation glioblastoma multiforme ( grade 4 astrocytoma ) determine preregistration central pathology review . NOTE : Variant gliosarcomas eligible 4 . Evidence tumor progression MRI CT scan follow RT follow recent antitumor therapy . Patients surgical treatment recurrence eligible image evidence disease progression compare first postoperative scan . 5 . Bidimensionally measurable evaluable disease MRI CT scan . 6 . ECOG Performance Status ( PS ) 0 , 1 , 2 . 7 . Patient willing discontinue use aspirin medication inhibit platelet function ≥ 1 week prior registration . 8 . Previous RT ≥12 week since completion RT prior registration . 9 . The following laboratory value obtain ≤ 21 day prior registration . ANC ≥1500 PLT ≥100,000 Hgb &gt; 9.0 g/dL T. bili ≤1.5 x ULN SGOT ( AST ) ≤ 3 x ULN Creatinine ≤ ULN 10 . UPC ratio &lt; 1 . NOTE : Urine protein must screen urine analysis Urine Protein Creatinine ( UPC ) ratio . For UPC ratio ≥1.0 , 24hour urine protein must obtain level &lt; 1000 mg 11 . Negative pregnancy test do ≤7 day prior registration , woman childbearing potential . 12 . Ability complete questionnaire ( ) assistance . 13 . Provide informed write consent 14 . Willingness return enrol institution followup . 15 . Patient willing provide mandatory tissue sample research purpose 16 . Study 1 : Any number prior chemotherapy regimens recurrent disease . Study 2 : Up 2 prior chemotherapy regimen ≤1 regimen recurrent disease . III . 1 . Pregnant woman , nurse woman men woman childbearing potential unwilling employ adequate contraception study 6 month bevacizumab treatment end . NOTE : bevacizumab dasatinib investigational agent whose genotoxic effect develop fetus newborn unknown . 2 . Prior intratumoral therapy , stereotactic radiosurgery , interstitial brachytherapy . EXCEPTION : Separate lesion MRI part previous treatment field , convince evidence recurrent disease , base biopsy , MRI spectroscopy , PET scan . 3 . Prior treatment bevacizumab VEGFTrap ( Aflibercept ) . 4 . Inadequately control hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg antihypertensive medication ) . NOTE : Patients wellcontrolled hypertension eligible . 5 . Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen . 6 . Immunocompromised patient ( relate use corticosteroid ) . NOTE : Patients know HIV positive , without clinical evidence immunocompromised state , eligible study . 7 . Any condition ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption ) impair ability swallow pill . 8 . Receiving therapeutic anticoagulation Warfarin . NOTE : Prophylactic anticoagulation ( i.e. , low dose warfarin ) venous arterial access device allow , provide INR &lt; 1.5 . Therapeutic anticoagulation low molecular weight heparin allow time registration . 9 . Evidence bleed diathesis ( great normal risk bleed ) coagulopathy ( absence therapeutic anticoagulation ) . 10 . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 11 . Receiving investigational agent would consider treatment primary neoplasm . 12 . Other active malignancy ≤3 year prior registration . EXCEPTIONS : Nonmelanotic skin cancer carcinoma insitu cervix . Note : If history prior malignancy , must receive specific treatment ( hormonal therapy ) cancer . 13 . History myocardial infarction unstable angina ≤6 month prior registration . 14 . New York Heart Association ( NYHA ) classification II , III IV congestive heart failure . 15 . Core biopsy minor surgical procedure ≤7 day prior registration . Note : Placement vascular access device allow . 16 . Major surgical procedure , open biopsy , significant traumatic injury ≤28 day prior registration anticipation need major surgical procedure course study . 17 . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) recent peripheral arterial thrombosis ≤6 month prior registration . 18 . History hypertensive crisis hypertensive encephalopathy . 19 . Known hypersensitivity component dasatinib bevacizumab . 20 . Serious , nonhealing wound , active ulcer , untreated bone fracture 21 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess ≤6 month prior registration . 22 . Active recent history hemoptysis ( ≥ ½ teaspoon bright red blood per episode ) ≤30 day prior registration . 23 . History stroke transient ischemic attack ( TIA ) ≤6 month prior registration . 24 . Any evidence CNS hemorrhage baseline CT MRI 25 . Any following Category I drug generally accept risk cause Torsades de Pointes ≤7 day prior registration ( patient must discontinue drug 7 day prior start dasatinib ) Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin , clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Prochlorperazine 26 . Diagnosed congenital long QT syndrome 27 . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de Pointes ) 28 . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) 29 . Patients may clinically significant cardiovascular disease include follow : Myocardial infarction ventricular tachyarrhythmia within 6 month . Prolonged QTc ≥ 480 msec ( Fridericia correction ) Ejection fraction less institutional normal Major conduction abnormality ( unless cardiac pacemaker present ) Note : Patients cardiopulmonary symptom unknown cause ( e.g. , shortness breath , chest pain , etc . ) evaluate baseline echocardiogram without stress test need addition electrocardiogram ( ECG ) rule QTc prolongation . The patient may refer cardiologist discretion principal investigator . Patients underlie cardiopulmonary dysfunction exclude study . 30 . Subjects hypokalemia hypomagnesemia correct prior dasatinib administration 31 . Known pleural pericardial effusion grade 32 . Concomitant use H2 blocker proton pump inhibitor discontinue switch locally act agent ( i.e . famotidine omeprazole . ) 33 . Use follow Enzyme Inducing AntiConvulsive ( EIAC ) medication prohibit ≤ 7 day prior registration : carbamazepine ( Tegretol® , Tegretol XR® , Carbatrol® ) , phenytoin ( Dilantin® , Phenytek® ) , fosphenytoin ( Cerebyx® ) , phenobarbital , pentobarbital primidone ( Mysoline® ) . Note : Many antiepileptic drug induce hepatic enzyme . Because dasatinib metabolize hepatic enzyme , patient take antiepileptic medication induce hepatic enzyme ( EIACs ) ineligible trial . To eligible trial , patient take EIACs must switch nonEIACs ≥ 7 day prior registration . The following agent know affect dasatinib metabolism acceptable use : valproic acid ( Depakote® , Depacon® ) , gabapentin ( Neurontin® ) , lamotrigine ( Lamictal® ) , topiramate ( Topamax® ) , tiagabine ( Gabitril® ) , zonisamide ( Zonegran® ) , levetiracetam ( Keppra® ) , clonazepam ( Klonopin® ) clobazam ( Frisium® ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
</DOC>